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SUMMARY 
A homogeneous enzyme-linked competitive-binding assay for biotin with glucose-6-phosphate 
dehydrogenase (GGPDH), is described. This assay is based on the interaction between a 
GGPDH/biotin conjugate with avidin, a natural binder for biotin. In the absence of biotin in the 
assay mixture, this interaction results in 100% inhibition of the enzyme conjugate. In the presence 
of biotin, the enzymatic activity of the conjugate is regained in an amount related to the concen- 
tration of the vitamin in the sample. Extremely steep, gate-like dose/response curves, attributable 
to the relative binding affinities of avidin for biotin and the conjugate, are observed. The detection 
limits of the system vary with the amounts of avidin and enzymelbiotin conjugate used. The 
method is rapid and sensitive and is evaluated for the direct determination of biotin in vitamin 
tablets. 
Binding proteins are naturally occurring macromolecules that exhibit high 
affinity and selectivity for selected biomolecules. In certain instances, such 
proteins possess the properties required to be used in place of antibodies in a 
variety of modern enzyme-linked competitive binding assays. Indeed, the ad- 
vantages of using endogenous binding proteins rather than antibodies in ho- 
mogeneous enzyme-linked assay arrangements have been demonstrated 
recently [ 1,2]. The simple assays devised for folate [l] and vitamin Blz [2] 
were rapid, selective, and exhibited unusually steep, gate-like dose/response 
behavior. This paper describes an analogous homogeneous competitive bind- 
ing assay for biotin based on an enzyme/biotin conjugate and avidin, a natural 
biotin binder. 
Biotin (vitamin H) is an important coenzyme in enzymatic carboxylation 
reactions requiring ATP [ 31. A deficiency of this vitamin results in anemia, 
dermatitis, desquamative erythroderma (Leiner’s disease in children), and 
biotin-related inborn errors of metabolism [ 41. Since its isolation in 1936 [ 51, 
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several methods have been developed for the determination of biotin (for ex- 
amples, see [6-141). Most of these conventional assays require separate ex- 
traction procedures and/or involve the use of costly equipment, reagents, etc. 
More recently, three separate homogeneous enzyme-linked assays for biotin 
based on competitive binding with avidin have been proposed [ 15-171; how- 
ever, these methods offered only marginal detection capabilities. The new 
method described here offers at least a 50-fold improvement in detection limits 
concomitant with much steeper dose/response curves. Further, it is demon- 
strated that it is feasible to prepare enzyme/ligand conjugates which can be 
inhibited up to 100% by low concentrations of the corresponding biological 
binder. This property combined with the intrinsic specificity and affinity of 
the avidin-biotin interaction results in a very fast, precise and selective method 
for detection of biotin. The analytical utility of the proposed assay procedure 
is demonstrated by determining biotin in commercial vitamin preparations. 
EXPERIMENTAL 
Apparatus and reagents 
A Gilford Stasar-III spectrophotometer equipped with a vacuum-operated 
sampling system and a temperature-controlled cuvette (thermostated at 30” C 
throughout the experiments) was used in the determination of enzyme activ- 
ities. This instrument was interfaced with a Syva CP-5000 EMIT clinical pro- 
cessor (set on delay and measurement times of 30 s). A Syva pipetter/diluter 
(Model 1500) was used to deliver volumes of the conjugate, the standards, the 
binder, and the samples. Throughout this study, the pipetter/diluter was set 
so it could deliver a reagent volume of 50 ,~l and dilute it with 100 ,ul of assay 
buffer solution (0.0500 M Tris-HCl, 0.100 M NaCl, 0.010% (w/v) sodium azide, 
pH 7.8). 
Gold-label dimethyl sulfoxide (DMSO) was purchased from Aldrich. Glu- 
cose-6-phosphate dehydrogenase (GGPDH) (from Leuconostoc mesenter- 
oides), d-biotin-N-hydroxysuccinimide and all the other chemicals used were 
from Sigma Chemical Co. and were of the highest purity available. Tris/gelatin 
buffer (1.0% gelatin in assay buffer) was used to prepare all the standards and 
to dilute the avidin, the enzyme, and the conjugates. 
Preparation of GGPDH/biotin conjugates 
The conjugates were prepared by reacting a quantity of GGPDH with differ- 
ent amounts of biotin-N-hydroxysuccinimide ester (dissolved in DMSO ) 
[ 1,181. The biotin ester solution (2 mg ml-’ ) was added in aliquots at lo-min 
intervals into a solution of 200 units of enzyme, which was previously dialyzed 
in 0.100 M NaHC03, pH 8.0 buffer. The protein solution was kept at 4°C 
during the addition of the ester. The conjugation reaction was run for 130 min 
at 4’ C with stirring, while the active site of the enzyme was protected by add- 
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ing an excess of glucose-6-phosphate and NADH compared to the amount of 
enzyme present [ 11. Finally, the conjugate was dialyzed against the assay buffer 
solution and diluted to a final volume of 2 ml. The protein concentration cor- 
respondingto this conjugate preparation was 2.6 ,uM (equivalent to 200 units 
of unmodified G6PDH). Variably substituted conjugates were prepared by us- 
ing different mole ratios of activated biotin/GGPDH. The percentage of resid- 
ual enzymatic activity of the conjugates was calculated by comparing the 
activities of conjugated enzyme to that of a solution containing unconjugated 
enzyme of the same protein concentration. 
Procedures 
Characterization of the conjugates. The enzymatic activity of the GGPDH 
conjugates was determined by measuring the rate of appearance of NADH at 
340 nm with the spectrophotometer [ 11. Measurements were taken after 30 s 
and 2 min and the enzymatic activity was calculated as the difference of these 
two absorbance values. When a (1 + 1999) dilution of conjugate was used, the 
enzymatic activity was calculated as the net change in absorbance measured 
between 30 s and 10 min. 
The kinetics of the association between 50 ,ul of a (1 + 99) dilution of the 
GGPDH/biotin conjugate and avidin were studied as described earlier [ 11. Di- 
lution curves for binding protein were used for further characterization of the 
conjugates. Using the pipeter/diluter, 50-~1 portions of solutions containing 
different concentrations of avidin in Tris-gelatin buffer were incubated with 
50 ~1 of a (1 + 99) dilution of the GGPDH/biotin conjugate, and 50 ,LL~ of Tris/ 
gelatin buffer. After 5 min of incubation at room temperature, the enzymatic 
activity of the reaction mixture was measured as above. A dilution curve for 
the binder was prepared by plotting percent inhibition vs. the amount of binder 
used. 
Dose/response curves. A stock solution of biotin (0.400 mM) was prepared 
by dissolving the corresponding amount of biotin in Tris/gelatin buffer. All 
the standards were made from dilutions of this stock solution with Tris/gelatin 
buffer. For the assay, 50 ~1 of the standards, 50 ~1 of a conjugate solution, and 
50 ~1 of an avidin solution were mixed and incubated at room temperature for 
5 min in a single incubation mode [ 191. The resulting enzymatic activity of 
the mixture was measured as above. A dose/response curve was prepared by 
plotting the percent inhibition vs. the logarithm of the concentration of the 
biotin in the standards. 
Vitamin tablets. Five tablets (Biotin, Thompson, and Biotin, Perrigo ) or 
ten tablets (Stress B-Complex, Bio-Genies) of each vitamin preparation were 
weighed and powdered [ 11. An amount of the powder corresponding to one 
tablet (Biotin, Thompson, and Biotin, Perrigo) or two tablets (Stress B-Com- 
plex, Bio-Genies) was weighed and shaken vigorously with 5.00 ml of 1.0 M 
NaOH for 15 min. The mixture was centrifuged at 2400 rpm for 10 min and 
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4.00 ml of the supernatant liquid was adjusted to a pH between 7 and 8 with 
hydrochloric acid. This preparation was then made to volume in a 25ml vol- 
umetric flask with Tris/gelatin buffer. Appropriate dilutions of the samples 
were prepared and processed by the procedure described above. For the recov- 
ery studies, a powdered amount of the Biotin preparation (Perrigo) corre- 
sponding to approximately 0.3 mg of biotin (quantity of biotin per tablet claimed 
on the label by the manufacturer) was weighed and mixed with 745 ,~l or 250 
~1 of a 0.100 mM biotin solution. Then, 5.00 ml of 1.0 M NaOH was added and 
the mixture was shaken for 15 min. The rest of the procedure was the same as 
for the vitamin tablet. All incubations in both real-sample analysis and recov- 
ery studies were done at room temperature. 
RESULTS AND DISCUSSION 
An ideal conjugate for homogeneous enzyme-linked competitive binding as- 
says should have high enzymatic activity and should be inhibited at or near 
100% by an excess of binder. Further, ideal conjugates should also have as low 
a degree of ligand substitution (average number of ligands attached per en- 
zyme molecule) as possible. The latter is necessary to obtain conjugates with 
favorable binding constants toward the respective binders. Indeed, for highly 
substituted conjugates, the statistical association constant between the binder 
and the conjugate is greatly increased [ 201 and this has been shown, theoret- 
ically, to result in assays with limited detection capabilities. The use of binding 
proteins instead of antibodies (which typically present bridging-group recog- 
nition problems [20] ) counteracts to some extent this inherent limitation of 
homogeneous competitive binding assays as has been demonstrated theoreti- 
cally (e.g., see Figs. 5 and 6 in [l] ). 
For the present study, several GGPDH/biotin conjugates were prepared with 
different mole ratios of biotin to enzyme. The various parameters character- 
izing the resulting conjugates are summarized in Table 1. In the presence of 
excess of avidin, several of the conjugates could be inhibited 100% (i.e., zero 
enzymatic activity). From Table 1, it can also be seen that increasing the initial 
molar ratio of biotin to enzyme results in a higher degree of conjugation as 
evidenced by the lower residual activities of the conjugates. Based on previous 
data [ 1,2], a comparison between conjugates of GGPDH with biotin, folate and 
vitamin Blz is shown in Table 2. While all conjugates were prepared by using 
similar reaction conditions [ 1,2], it is clear that the biotin system yields con- 
jugates with the highest inhibition for the same initial mole ratio of ligand to 
enzyme. The conjugate prepared with a 100 : 1 mole ratio of biotin to enzyme, 
BC-1, which had a maximum inhibition of 98% was used in all subsequent 
experiments. 
It is known that in order for avidin to bind biotin, the carboxylic group of 
the latter has to be at least 9 A from the surface of the protein (i.e., biotin is 
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TABLE 1 
Parameters of GGPDH/biotin conjugates 







BC-1 100 26 98 
BC-2 200 11 100 
BC-3 500 4.8 100 
BC-4 1000 1.2 100 
“To determine the % inhibition, an excess of avidin was used with (1+99) dilutions of BC-1 and 
BC-2, and (1 + 19) dilutions of BC-3 and BC-4. The conjugates and the avidin were incubated for 
5 min before the enzymatic activity was measured. 
essentially buried within the binding site of avidin) [ 21,221. However, the link 
provided by the lysine residue in biotinylated GGPDH allows only for 7.1 A 
between the carboxylic group of biotin and the polypeptide chain. Therefore, 
we believe that in the case of enzyme/biotin conjugates, formation of the avi- 
din-biotin complex will bring the avidin right on the surface of the conjugate 
resulting in 100% inhibition. 
The effect of changing the reaction time between avidin and the conjugate 
BC-1 was studied (association kinetics study) (Fig. 1). Extremely small quan- 
tities of avidin in the assay, 125 ng (50 ~1 of 2.5 pg ml-l solution of avidin) 
and 62.5 ng (50 ,A of 1.25 ,ug ml-’ solution of avidin), were capable of inhibiting 
the enzyme conjugate up to 87% and 58%, respectively, after a 40-min reaction 
period. However, within 5 min, 93% and 89% of the maximum inhibition was 
observed, respectively. Thus, to increase the speed of the biotin assays, a 5- 
min incubation time period was chosen for the remaining studies. It should be 
TABLE 2 
Comparison of GGPDH/ligand conjugates 
Initial ratio” 
(ligand/GGPDH) 
Inhibition ( % ) 
GGPDH/biotin GGPDH/vitamin B,, GGPDH/folate 
100 98 19 













lncubaiion Time (min) Amount of Avidm (ng) 
Fig. 1. Association curve for a (1+99) dilution of BC-1 with two dilutions of avidin: (0 ) 2.5 ,ug 
ml-’ avidin; ( 0 ) 1.25 pg ml-’ avidin. The incubation time was varied from zero (minimum time 
required to mix the reagents and measure the enzymatic activity) to 40 min. Data points are means 
of duplicate measurements. 
Fig. 2. Effect of varying the levels of avidin (ng of avidin in assay mixture) on the inhibition of a 
(1 + 99) dilution of BC-1. Values shown are means of duplicate measurements. 
noted that conjugate BC-3 exhibited 100% inhibition even when the incuba- 
tion time approached zero (i.e., measuring the enzymatic activity right after 
mixing the reagents). To our knowledge, this is the first time that, even with- 
out any incubation, such a high inhibition has been observed in this type of 
homogeneous assay. 
When compared with the association curves previously obtained using a 
GGPDH/folate conjugate with folate-binding protein [II and a 
GGPDH/vitamin B12 conjugate with R-protein [ 21, the curves of Fig. 1 indi- 
cate a much faster association between BC-1 and avidin as indicated by the 
initial slope of the association curve. This can be partly explained by the ex- 
pected relatively high value for the association rate constant between the 
GGPDH/biotin and avidin. Indeed, the rate constant for the interaction of 
biotin and avidin has been estimated at 7 x lo7 M-’ s-l [ 221. For comparison, 
a value of lOa M-’ s-l is the proposed diffusion-controlled limit for this rate 
constant if the electrostatic repulsion between the ligand and the binder are 
taken into account [ 231. 
For the binder-dilution studies, different amounts of avidin were incubated 
for 5 min with the same amount of conjugate (50 ,~l of a (1 + 99) dilution of 
BC-1) . As shown in Fig. 2, the more avidin in the assay, the more the conjugate 
is inhibited by the binder. This conjugate was 97% inhibited when incubated 
for 5 min with 500 ng of avidin (50 ,~l of a 10.0 pg ml-’ avidin solution). 
A typical dose/response curve obtained by using a 14.3 ,ug ml-’ avidin so- 
lution and a (1 + 99) dilution of BC-1 is shown in Fig. 3. The solid line corre- 
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Fig. 3. Typical dose/response curve for biotin. Error bars are k 1 s.d. (n =5). Conditions: (1+99) 
dilution of BC-1 and 14.3 pg ml-’ avidin solution. The x-axis refers to concentrations of biotin in 
the standards. 
Fig. 4. Effects of various conjugate and avidin concentrations on the dose/response curve. Means 
of duplicate measurements were plotted. The reagent concentrations used were as follows: ( V ) 
0.714 pg ml-’ avidin, (1 + 1999) dilution BC-1; (0 ) 7.14 .ug ml-’ avidin, (1+99) dilution BC-1; 
(A ) 7.14pgml-’ avidin, (l+ 199) dilution BC-1; (0) 14.3pgml-’ avidin, (1+99) dilution BC- 
1; (A ) 14.3 fig ml-’ avidin, (1 + 199) dilution BC-1. Biotin concentration refer to the standards 
used. 
sponds to the average inhibition for five separate measurements. The 
reproducibility of this method is demonstrated by the error bars ( + 1 s.d.). 
The standard deviation for each biotin concentration was calculated as de- 
scribed previously [ 11. As shown, the curve is extremely steep over a very nar- 
row concentration range. Indeed, 77% inhibition was observed at 0.500 ,uM 
biotin concentration in the standard, while the conjugate is inhibited by only 
21% when the biotin concentration in the standard was increased to just 0.800 
PM. As expected, the standard deviation (with respect to inhibition) is higher 
at the steep portion of the dose/response curve and more or less constant over 
the remainder of the curve. As suggested by Rodbard [ 241, this type of curve 
may be useful in calculating an approximate percent error corresponding to a 
dose estimate. For example, according to Fig. 3, an inhibition of 50% will cor- 
respond to a biotin concentration of 0.578 PM with an associated relative error 
of + 2.2% (estimated as suggested in [ 241). 
The effect of varying the concentration of avidin and conjugate on the per- 
formance of the assays was evaluated. The results, summarized in Fig. 4, in- 
dicate that the ED,, value of the dose/response curve is greatly dependent on 
the amount of avidin present. Thus, the ED,, is shifted by approximately half 
when the concentration of avidin in the assay mixture is halved. Similarly, 
reducing the concentration of avidin ten-fold was also observed to decrease the 
ED,, value by approximately an order of magnitude. In general, the greater the 
concentration of binder in the assay, the steeper the dose/response curve, the 
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greater the maximum inhibition, and the poorer the EDE, values. When more 
dilute solutions of avidin and biotin/GGPDH were used, an improvement of 
detection limits was observed at the expense of a decrease in the steepness of 
the dose/response curve. 
By using a 0.714 pg ml-’ solution of avidin and a (1+ 1999) dilution of BC- 
1, concentrations of biotin down to 8 nM (concentration of biotin in the sam- 
ple) which corresponds to 1 pg of biotin, could be determined. The concentra- 
tion of biotin in the assay mixture is one ninth of the latter which corresponds 
to a detection limit of approximately 0.9 nM biotin in the assay. This is a 50-, 
110- and 500-fold improvement over the detection limits reported by Niedbala 
et al. [ 171, Gebauer and Rechnitz [ 151, and Ngo et al. [ 161, respectively. Fur- 
ther, the sensitivity (steepness of the dose/response curve) of the previous 
biotin assays is inferior by at least an order of magnitude when compared to 
that reported here [ 15-171. Even better detection limits may be obtained with 
this new assay by using even lower concentrations of reagents. The latter, how- 
ever, will be at the expense of an increase in the time needed for the overall 
assay. 
The improved detection limits that were observed here, compared to the 
ones reported earlier [ 15,161, can be explained by the fact that in the present 
experiments, the conjugation of the enzyme was done in the presence of G6P 
and NADH in order to protect the active site of the enzyme. Therefore, the 
conjugates lose less activity during conjugation which leads to assays with in- 
creased sensitivity. Further, compared to the work of Niedbala et al. [ 171, the 
present lower detection limits can be attributed to the fact that the conjugate 
preparation shows higher inhibition in the presence of a smaller amount of 
avidin. Specifically, the conjugate BC-1 was inhibited more than 80% in the 
assay with 36 ng of avidin, whereas in the earlier assay [ 171 an amount of 500 
ng of avidin was needed to achieve 70% inhibition (in both assays the concen- 
tration of conjugate was approximately the same). 
Figure 4 also indicates that when either a 14.3 ,ug ml-l or a 7.14 pg ml-’ 
solution of avidin was used, the ED,, value (effective dose at 50% of maximum 
response) was virtually independent on whether a (1 + 99) or (1+ 199) dilu- 
tion of BC-1 was used. These observations agree well with previous theoretical 
predictions for such enzyme-linked assay systems [20]. Indeed, from earlier 
work (Fig. 5 in [ 201)) it can be inferred that when the concentration of binder 
is much higher than the concentration of conjugate (as is the case in the assay 
described here) changes in the concentration of the latter do not affect the 
ED,, value substantially. The same theoretical model also predicts extremely 
steep dose/response behavior whenever the binder associates more strongly 
with the analyte than the enzyme-labeled ligand [ 11. This is likely to occur 
when natural binding proteins such as avidin are used. 
The long-term stability of the dose/response curves was evaluated by com- 
paring their ED,, values over a 35day period for a given binder (14.3 ,ug ml-’ ) 
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TABLE 3 
Results for selected vitamin tablets 
Vitamin tablet Amount of biotin per 
tablet @g(p) 
Recovery study 






Stress B Complexb 12.5 12.5 - - - 
Biotin” 150 150 - - - 
Biotind 291 300 73.3 76.2 104 
147 149 101 
“Average of two determinations. bBio-Genics, Canoga Park, CA; these tablets also contained vi- 
tamins B1, Bz, B, (5 mg each) and B,, (12.5 pg) with niacin, calcium d-pantothenate, choline 
bitartrate and inositol(50 mg each), folic acid (0.2 mg ) , vitamin C (75 mg ) and p-aminobenzoic 
acid (15 mg). ‘Wm.T. Thompson Co., Carson, CA. dPerrigo, Allegan, MI. 
and conjugate concentration (1 + 99 dilution). The ED5,, value of a typical 
dose/response curve fell within the range of 0.566 PM to 0.578 PM (for three 
random observations). 
To demonstrate the feasibility of using this new assay for real samples, the 
determination of biotin in three different commercial vitamin preparations 
was undertaken. Table 3 summarizes the results of the assays. The amounts 
of biotin found were within 3% of the amount claimed by the manufacturers. 
The data for the multivitamin tablet also demonstrate the high selectivity of 
the assay in practical situations. The results of the recovery study are also 
shown in Table 3; the excellent recoveries suggest the absence of matrix effects. 
In conclusion, the assay can detect as little as 8 nM biotin in samples (or 
equivalently, 1 pg of biotin in the assay) which is orders of magnitude better 
than the existing homogeneous competitive binding methods. Because of the 
extreme steepness of the dose/response curves, this assay method may find 
applications in quality control situations, where a decision on whether or not 
a product has a biotin content higher than a minimum cutoff level has to be 
made. 
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